Anti-inflammatory effects of resveratrol in patients with cardiovascular disease: A systematic review and meta-analysis of randomized controlled trials.
CRP
Cardiovascular disease
Inflammation
Resveratrol
TNF-α
Journal
Complementary therapies in medicine
ISSN: 1873-6963
Titre abrégé: Complement Ther Med
Pays: Scotland
ID NLM: 9308777
Informations de publication
Date de publication:
Nov 2022
Nov 2022
Historique:
received:
07
03
2022
revised:
23
07
2022
accepted:
25
07
2022
pubmed:
30
7
2022
medline:
31
8
2022
entrez:
29
7
2022
Statut:
ppublish
Résumé
Chronic inflammation is one of the most important factors involved in the development and progression of cardiovascular disease (CVDs). Accumulating evidence has described the effect of resveratrol, a natural polyphenolic compound, on biomarkers of inflammation among patients with CVDs; however, findings are controversial. Here we performed a systematic review and meta-analysis of randomized controlled trials to evaluate the effect of resveratrol supplements on TNF-α, IL-6, and CRP levels in CVDs patients. Online research was conducted in the following database: MEDLINE, EMBASE, Cochrane Library, Web of Science databases, and Scopus. This systematic review and meta-analysis were conducted to investigate the effects of resveratrol supplements on inflammatory biomarkers among patients with CVDs. The meta-analysis was performed using Comprehensive Meta-Analysis (CMA) V3 software. Six RCTs met the inclusion criteria and were selected for the current meta-analysis. Our results demonstrated that resveratrol significantly decreases serum levels of CRP (MD = -0.63, 95 % CI: -0.1.13, -0.12; p = 0.01), and TNF-α (MD = -0.55, 95 % CI: -1.04, -0.06; p = 0.02), however, resveratrol had not significant effect on serum concentration of IL-6 (MD = -0.12, 95 % CI: -0.52, 0.27; p = 0.53), in patients with CVDs. Our results suggest that resveratrol can be used as a potential treatment in patients with CVD by reducing inflammatory conditions.
Sections du résumé
BACKGROUND
BACKGROUND
Chronic inflammation is one of the most important factors involved in the development and progression of cardiovascular disease (CVDs). Accumulating evidence has described the effect of resveratrol, a natural polyphenolic compound, on biomarkers of inflammation among patients with CVDs; however, findings are controversial. Here we performed a systematic review and meta-analysis of randomized controlled trials to evaluate the effect of resveratrol supplements on TNF-α, IL-6, and CRP levels in CVDs patients.
METHODS
METHODS
Online research was conducted in the following database: MEDLINE, EMBASE, Cochrane Library, Web of Science databases, and Scopus. This systematic review and meta-analysis were conducted to investigate the effects of resveratrol supplements on inflammatory biomarkers among patients with CVDs. The meta-analysis was performed using Comprehensive Meta-Analysis (CMA) V3 software.
RESULTS
RESULTS
Six RCTs met the inclusion criteria and were selected for the current meta-analysis. Our results demonstrated that resveratrol significantly decreases serum levels of CRP (MD = -0.63, 95 % CI: -0.1.13, -0.12; p = 0.01), and TNF-α (MD = -0.55, 95 % CI: -1.04, -0.06; p = 0.02), however, resveratrol had not significant effect on serum concentration of IL-6 (MD = -0.12, 95 % CI: -0.52, 0.27; p = 0.53), in patients with CVDs.
CONCLUSION
CONCLUSIONS
Our results suggest that resveratrol can be used as a potential treatment in patients with CVD by reducing inflammatory conditions.
Identifiants
pubmed: 35905799
pii: S0965-2299(22)00065-6
doi: 10.1016/j.ctim.2022.102863
pii:
doi:
Substances chimiques
Anti-Inflammatory Agents
0
Biomarkers
0
Interleukin-6
0
Tumor Necrosis Factor-alpha
0
Resveratrol
Q369O8926L
Types de publication
Journal Article
Meta-Analysis
Review
Systematic Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
102863Informations de copyright
Copyright © 2022 The Authors. Published by Elsevier Ltd.. All rights reserved.